130 related articles for article (PubMed ID: 21397718)
61. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
[TBL] [Abstract][Full Text] [Related]
62. Approaches to the construction of new candidate poliovirus type 3 vaccine strains.
Almond JW; Stone D; Burke K; Skinner MA; Macadam AJ; Wood D; Ferguson M; Minor PD
Dev Biol Stand; 1993; 78():161-9; discussion 169-70. PubMed ID: 8388827
[TBL] [Abstract][Full Text] [Related]
63. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains.
Hamidi A; Bakker WA
Pharm Pat Anal; 2012 Nov; 1(5):589-99. PubMed ID: 24236927
[TBL] [Abstract][Full Text] [Related]
64. VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.
Dawson ED; Taylor AW; Johnson JE; Hu T; McCormick C; Thomas KN; Gao RY; Wahid R; Mahmood K; Rowlen KL
J Immunol Methods; 2022 May; 504():113259. PubMed ID: 35314144
[TBL] [Abstract][Full Text] [Related]
65. Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine "PoliovacSin": Clinical Trials Phase I and II.
Piniaeva A; Ignatyev G; Kozlovskaya L; Ivin Y; Kovpak A; Ivanov A; Shishova A; Antonova L; Khapchaev Y; Feldblium I; Ivanova O; Siniugina A; Ishmukhametov A
Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34072466
[TBL] [Abstract][Full Text] [Related]
66. Mathematical model of adherent Vero cell growth and poliovirus production in animal component free medium.
Ursache RV; Thomassen YE; van Eikenhorst G; Verheijen PJ; Bakker WA
Bioprocess Biosyst Eng; 2015 Mar; 38(3):543-55. PubMed ID: 25294335
[TBL] [Abstract][Full Text] [Related]
67. Effects of arildone on the immunogenicity of formalin-inactivated polioviruses.
Abe S; Yamaki A; Doi Y; Yoshioka I
Jpn J Med Sci Biol; 1987 Feb; 40(1):1-13. PubMed ID: 3041077
[TBL] [Abstract][Full Text] [Related]
68. A simple and safe antibody neutralization assay based on polio pseudoviruses.
Jiang Z; Liu G; Guo-Yang L; Sun M; Xu K; Ying Z; Wang J; Li X; Li C
Hum Vaccin Immunother; 2019; 15(2):349-357. PubMed ID: 30273512
[TBL] [Abstract][Full Text] [Related]
69. Method for the simultaneous assay of the different poliovirus types using surface plasmon resonance technology.
Manin C; Naville S; Gueugnon M; Dupuy M; Bravo de Alba Y; Adam O
Vaccine; 2013 Feb; 31(7):1034-9. PubMed ID: 23277095
[TBL] [Abstract][Full Text] [Related]
70. The preparation of specific immune sera against type 3 poliovirus D-antigen and C-antigen and the demonstration of two C-antigenic components in vaccine strain populations.
Minor PD; Schild GC; Wood JM; Dandawate CN
J Gen Virol; 1980 Nov; 51(Pt 1):147-56. PubMed ID: 6161996
[TBL] [Abstract][Full Text] [Related]
71. Identification of the epitope in human poliovirus type 1 Sabin strain recognized by the monoclonal antibody 1G10 using mimotope strategy.
Bai H; Liu S; Shi S; Lu W; Yang Y; Zhu Y; Zhang Z; Guo H; Li X
J Virol Methods; 2020 Feb; 276():113791. PubMed ID: 31778678
[TBL] [Abstract][Full Text] [Related]
72. An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16.
Jenkins O; Cason J; Burke KL; Lunney D; Gillen A; Patel D; McCance DJ; Almond JW
J Virol; 1990 Mar; 64(3):1201-6. PubMed ID: 2154604
[TBL] [Abstract][Full Text] [Related]
73. Evaluation of the use of various rat strains for immunogenic potency tests of Sabin-derived inactivated polio vaccines.
Someya Y; Ami Y; Takai-Todaka R; Fujimoto A; Haga K; Murakami K; Fujii Y; Shirato H; Oka T; Shimoike T; Katayama K; Wakita T
Biologicals; 2018 Mar; 52():12-17. PubMed ID: 29475730
[TBL] [Abstract][Full Text] [Related]
74. Layer-by-Layer Assembly of Inactivated Poliovirus and N-Trimethyl Chitosan on pH-Sensitive Microneedles for Dermal Vaccination.
van der Maaden K; Sekerdag E; Schipper P; Kersten G; Jiskoot W; Bouwstra J
Langmuir; 2015 Aug; 31(31):8654-60. PubMed ID: 26145437
[TBL] [Abstract][Full Text] [Related]
75. Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines.
Fox H; Knowlson S; Minor PD; Macadam AJ
PLoS Pathog; 2017 Jan; 13(1):e1006117. PubMed ID: 28103317
[TBL] [Abstract][Full Text] [Related]
76. Trypsin diminishes the rat potency of polio serotype 3.
ten Have R; Westdijk J; Levels LM; Koedam P; de Haan A; Hamzink MR; Metz B; Kersten GF
Biologicals; 2015 Nov; 43(6):474-8. PubMed ID: 26321654
[TBL] [Abstract][Full Text] [Related]
77. Inactivation of poliovirus with beta-propiolactone.
Jiang SD; Pye D; Cox JC
J Biol Stand; 1986 Apr; 14(2):103-9. PubMed ID: 3020055
[TBL] [Abstract][Full Text] [Related]
78. A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines.
Wood DJ; Heath AB; Sawyer LA
Biologicals; 1995 Mar; 23(1):83-94. PubMed ID: 7619442
[TBL] [Abstract][Full Text] [Related]
79. Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine.
Moon SS; Richter-Roche M; Resch TK; Wang Y; Foytich KR; Wang H; Mainou BA; Pewin W; Lee J; Henry S; McAllister DV; Jiang B
NPJ Vaccines; 2022 Feb; 7(1):26. PubMed ID: 35228554
[TBL] [Abstract][Full Text] [Related]
80. Swedish inactivated polio vaccine: laboratory standardization and clinical experience over a 30-year period.
Böttiger M; Larsson B
Biologicals; 1992 Dec; 20(4):267-75. PubMed ID: 1305403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
